홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

카부트아미트

Carbutamide

HCID 9564
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
339-43-5
표준 SMILES
CCCCNC(=O)NS(=O)(=O)c1ccc(N)cc1
InChIKey
VDTNNGKXZGSZIP-UHFFFAOYSA-N
분자식
C11H17N3O3S
평균 분자량
271.34 g/mol
단동위원소 질량
271.09906259

개요

Carbutamide is a member of benzenes and a sulfonamide.

이름 및 식별자

우선 이름
Carbutamide
IUPAC
1-(4-aminophenyl)sulfonyl-3-butylurea
현지명
카부트아미트
영어명
carbutamide
분자식
C11H17N3O3S
분자량
271.34

이름 및 동의어

Carbutamide339-43-5GlybutamideButisulfinaGlucidoralEmedanInvenolGlucofrenDiaboralAminophenurobutaneNorboralOrasulin
이름 더 보기
카부트아미트카부트아마이드U-6987OranilBucarban
BurcolNadisanOranylBukarbanAlentinBucrolInbutonNadizan

데이터베이스 식별자

CAS
339-43-5
PubChem CID
9564
DTXSID
DTXSID8022741
ChEMBL
CHEMBL448570
ChEBI
CHEBI:135118
UNII
E3K8P4869P
EC Number
206-424-4
Nikkaji
J5.684G

물성

구조 계산 물성보충 중

XLogP
1
극성 표면적
110 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
4
회전 가능 결합 수
5
무거운 원자 수
18
형식 전하
0
복잡도
356

실험 및 물리화학적 성질

SpringerMaterials PropertiesCrystal structure
LogP · 2건

log Kow= 1.01

1.18

Color/FormCrystals
Solubility · 2건

Sol in water at pH 5 to 8.

In water, 535 mg/l @ 37 °C

Melting Point144-145 °C
Collision Cross Section165.0 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID8022741]

물리화학적 성질

녹는점
144 · 144-145°
밀도
1.284 · 1.2840 (rough estimate)
굴절률
1.663 · 1.6630 (estimate)
저장 조건
Refrigerator
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태
고체
산도 계수 (pKa)
5.75 · pKa 5.75(H2O t=25±0.02 I=0.2) (Uncertain)
색상
미색부터 페일 베이지까지
수용성
535.2 mg/L · 535.2mg/L(37℃)
EPA
4 · Benzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]- (339-43-5)

화학적 성질

Off-White to Pale Peach Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H315 (97.5%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Other Safety InformationIMAP assessments - Benzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]-: Human health tier I assessment
FDA Requirements · 1건

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesSkin Irrit. 2 (97.5%)

안전 및 보호

Disposal Methods · 1건

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

독성 정보

Interactions · 5건

...SODIUM CARBONATE REDUCED...DRUG'S TERATOGENIC & LETHAL ACTION IN RAT.

DRUGS THAT MAY INCR RISK OF HYPOGLYCEMIA FROM SULFONYLUREAS INCL OTHER HYPOGLYCEMIC AGENTS, SULFONAMIDES, PROPRANOLOL, SALICYLATES, CLOFIBRATE, PHENYLBUTAZONE, PROBENECID, DICUMAROL, CHLORAMPHENICOL, MONOAMINE OXIDASE INHIBITORS, & ALCOHOL. /SULFONYLUREAS/

ALCOHOL & SALICYLATES BECAUSE OF THEIR DIRECT HYPOGLYCEMIC ACTION, MAY PRECIPITATE HYPOGLYCEMIC COMA IN PT RECEIVING SULFONYLUREAS. ... PROPRANOLOL, BY INTERFERING WITH GLYCOGENOLYSIS & GLUCAGON RELEASE, ENHANCES THE HYPOGLYCEMIC ACTION OF SULFONYLUREAS. /SULFONYLUREAS/

THE SULFONYLUREA-MEDIATED SECRETION OF INSULIN CAN BE MODIFIED BY CONCOMITANT PERFUSION OF SECOND DRUG THAT DISPLACES SULFONYLUREA IN PANCREAS. THUS, THE DRUG INTERACTION AT THE TARGET ORGAN OR RECEPTOR SITE SHOULD BE UNDERSTOOD TO PROVIDE ADEQUATE DRUG THERAPY.

For more Interactions (Complete) data for 1-BUTYL-3-SULFANILYLUREA (8 total), please visit the HSDB record page.

Human Toxicity ExcerptsFOURTEEN PT TREATED WITH CARBUTAMIDE HAD TRANSIENT HEMIPARESIS. 4 HAD IRREVERSIBLE NEUROLOGIC DEFECTS, & 5 EXPIRED AFTER HYPOGLYCEMIC COMA. NEARLY 70 OF THE EPISODES OCCURRED WITHIN THE FIRST 15 DAYS OF THE SULFONYLUREA TREATMENT.
Non-Human Toxicity Excerpts · 5건

CARBUTAMIDE...HAS BEEN SHOWN TO BE TOXIC TO THE EYES OF RATS WHEN CHRONICALLY ADMIN AT DOSAGES 5 TO 40 TIMES THOSE EMPLOYED IN TREATMENT OF HUMAN BEINGS. IT HAS CAUSED OPACIFICATION OF LENS & CORNEA, VASCULARIZATION OF CORNEA, & POSTERIOR SYNECHIAS, USUALLY IN 8-24 MO. ... IN DOGS SIMILAR TREATMENT HAS NOT AFFECTED EYES.

...CLEFT PALATE, EYE DEFECTS & GENERALIZED EDEMA /WAS FOUND/ IN RAT FETUSES WHOSE MOTHERS RECEIVED 500 MG/DAY FOR 1, 2 OR 3 DAYS DURING THE EMBRYONIC PERIOD.

...800 MG/KG FROM 1ST THROUGH 12TH DAY /OF GESTATION/ IN RATS PRODUCED 10-33% MALFORMED FETUSES. MAJORITY OF DEFECTS INVOLVED EYE & INCL ABSENCE OF OPTIC NERVE. SOME NERVOUS SYSTEM DEFECTS...REPORTED. ... /ANOTHER INVESTIGATOR/...CAUSED CLEFT PALATES & HYDROCEPHALUS WITH THIS SUBSTANCE IN RATS.

CARBUTAMIDE WAS ADMIN PARENTERALLY IN DOSES OF 100 MG/KG BODY WT & WAS WELL TOLERATED. FOLLOWING TREATMENT ON DAYS 4, 5, & 6 NO ABNORMALITIES WERE SEEN IN 6 1/2 DAY BLASTOCYSTS. NO EFFECT ON FETAL DEVELOPMENT.

For more Non-Human Toxicity Excerpts (Complete) data for 1-BUTYL-3-SULFANILYLUREA (13 total), please visit the HSDB record page.

규제 정보

FDA Requirements · 1건

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

안전 데이터

tsca
TSCA listed
독성
LD50 s.c. in mice: 3 g/kg (Haack, Hagedorn)
유해 물질 데이터
339-43-5(Hazardous Substances Data)

화학 및 산업

약리 정보

ATC Code · 2건

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Mechanism of Action · 1건

SULFONYLUREAS STIMULATE ISLET TISSUE TO SECRETE INSULIN. ... SULFONYLUREAS CAUSE DEGRANULATION OF THE BETA CELLS, A PHENOMENON ASSOCIATED WITH INCR RATE OF SECRETION OF INSULIN. ...THEY ARE EFFECTIVE IN INSULIN-INDEPENDENT DIABETIC PATIENTS IN WHOM THE PANCREAS RETAINS THE CAPACITY TO SECRETE INSULIN. /SULFONYLUREAS/

Metabolism/Metabolites · 2건

...IN MAN APPROX ONE-THIRD OF THE EXCRETED DOSE IS REPRESENTED BY THE N-ACETYLATED METABOLITE. LARGE SPECIES VARIATIONS HAVE BEEN DETECTED; THE RABBIT PRODUCES SIGNIFICANT AMT...WHILE MONKEY & DOGS ARE LOW OR VERY LOW ACETYLATORS & MAN OCCUPIES AN INTERMEDIATE POSITION.

THEY ARE HYDROXYLATED IN THE LIVER TO ACTIVE & INACTIVE PRODUCTS WHICH ARE ALMOST TOTALLY EXCRETED IN THE URINE. /SULFONYLUREAS/

MeSH Pharmacological ClassificationSubstances which lower blood glucose levels.
Absorption, Distribution and Excretion · 2건

THE SULFONYLUREAS ARE READILY ABSORBED FROM THE GI TRACT. THE MOST IMPORTANT DIFFERENCE AMONG THE SULFONYLUREAS, FOR CLINICAL PURPOSE, IS IN THEIR DURATION OF ACTION... /SULFONYLUREAS/_

SULFONYLUREAS ARE LARGELY BOUND TO PLASMA PROTEINS & ARE DISTRIBUTED IN THE EXTRACELLULAR SPACE. /SULFONYLUREAS/

용도 및 제조

Uses · 2건

Therap cat: Antidiabetic

MEDICATION (VET)

U.S. Production · 2건

(1979) NOT PRODUCED COMMERCIALLY IN U.S.

(1981) NOT PRODUCED COMMERCIALLY IN U.S.

Methods of Manufacturing · 2건

...from butylurea and sulfanilamide: Samaniego, Spanish patent 229,696 (1956), CA 51, 7413 (1957); Haack, Hagedorn, US patent 2,907,692 (1959 to Boehringer, Mann). Alternate route: Haack, Hagedorn, US patent 2,997,375 (1961 to Boehringer, Mann).

REACTION OF BUTYLUREA WITH SULFANILAMIDE

General Manufacturing InformationBenzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]-: INACTIVE

응용 분야

용도Antidiabetic.

상·하류 제품 정보

상류 원료

이소티오시안산부틸에스테르아질산 나트륨

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트